Sanofi SA (EPA: SAN) was the recipient of a ratings changes during the seven days:

  • Sanofi SA had its “buy” rating reaffirmed by analysts at Societe Generale. They now have a $98.72 (€76) price target on the stock.
  • Sanofi SA had its “buy” rating reaffirmed by analysts at Bryan Garnier & Cie. They now have a $102.56 (€79) price target on the stock.
  • Sanofi SA had its “accumulate” rating reaffirmed by analysts at Helvea. They now have a $100.00 (€77) price target on the stock.
  • Sanofi SA had its “outperform” rating reaffirmed by analysts at Exane BNP Paribas. They now have a $96.15 (€74) price target on the stock.
  • Sanofi SA had its “hold” rating reaffirmed by analysts at CIC Securities. They now have a $74.03 (€57) price target on the stock.
  • Sanofi SA had its “hold” rating reaffirmed by analysts at Independent Research GmbH. They now have a $92.31 (€71) price target on the stock.
  • Sanofi SA had its “underweight” rating reaffirmed by analysts at Liberum Capital Ltd. They now have a $84.42 (€65) price target on the stock.

Sanofi SA traded down 1.47% on Tuesday, hitting €66.80. Sanofi SA has a 1-year low of €18.32 and a 1-year high of €24.65. The company has a market cap of €88.026 billion and a price-to-earnings ratio of 13.97.

Sanofi SA, formerly Sanofi-Aventis, is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients’ needs.